Nuvilex Reports Additional Safety and Efficacy Data From Second Phase 2 Pancreatic Cancer Trial
Published: Oct 08, 2012
SILVER SPRING, Md., Oct. 8, 2012 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology provider of cell and gene therapy solutions, announced the presentation today of additional safety and efficacy data from a second Phase 2 pancreatic cancer clinical trial. The new trial data was presented by Dr. John Dangerfield, COO of the Nuvilex subsidiary Austrianova Singapore Pte Ltd (ASPL) at the ISCGT Meeting. The trial data presented used the same encapsulated cytochrome P450 expressing cells followed by chemotherapy to treat pancreatic cancer that were used in the previously published trial and confirmed results generated in the previous trial.